Why Bristol-Myers Squibb Ending A Drug Trial Early Is A Good Thing

Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick..

TheStreet Senior Columnist Adam Feuerstein discussed Bristol-Myers Squibb Co BMY on the show.


Feuerstein pointed out that the company announced Friday that it stopped a lung cancer drug trial early.

The news was positive because, according to Feuerstein, the drug was working so well and had “overwhelming efficacy.”

“That’s just more good news for Bristol-Myers,” Feuerstein said, as it would fuel further investor interest in cancer immunotherapy stocks.

Bristol-Myers recently traded at $65.49, up 2.84 percent.

Check out the full interview below. Feuerstein comes in at about the 1-hour mark: